US Patent

US9248229 — Packaging system for oxygen-sensitive drugs

Formulation · Assigned to Becton Dickinson France SA · Expires 2034-03-12 · 8y remaining

Vulnerability score 42/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects a packaging system for oxygen-sensitive drugs, including morphine sulfate, that prevents oxidative degradation.

USPTO Abstract

Described herein are pharmaceutical packaging systems which prevent oxidative degradation of morphine, hydromorphone, promethazine and other oxygen-sensitive drugs, such systems including a syringe with an oxygen permeable tip cap, a hermetically sealed oxygen barrier blister packaging with very low permeability to oxygen and comprises ethylene vinyl, and an oxygen absorber.

Drugs covered by this patent

chembl-chembl2103744 (MORPHINE SULFATE)
Dilaudid-Hp (Hydromorphone Hydrochloride) · Fresenius Kabi

Patent Metadata

Patent number: US9248229
Jurisdiction: US
Classification: Formulation
Expires: 2034-03-12
Drug substance claim: No
Drug product claim: Yes
Assignee: Becton Dickinson France SA
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.